Jasper Therapeutics (NASDAQ:JSPR) Stock Rating Lowered by Wall Street Zen

Jasper Therapeutics (NASDAQ:JSPR) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

JSPR has been the subject of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Piper Sandler initiated coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They set an “overweight” rating and a $2.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.17.

Jasper Therapeutics Price Performance

JSPR opened at $0.62 on Friday. The business’s 50-day moving average is $0.71 and its two-hundred day moving average is $0.78. Jasper Therapeutics has a 1 year low of $0.32 and a 1 year high of $2.69. The firm has a market capitalization of $20.56 million, a PE ratio of -0.39 and a beta of 3.04.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Friday, August 14th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. As a group, sell-side analysts expect that Jasper Therapeutics will post -1.14 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc is a clinical-stage biotechnology company developing antibody therapies for diseases driven by mast cells and for conditions requiring the controlled depletion of blood-forming stem cells. The company’s research is centered on targeting c-Kit, a receptor involved in the survival and development of mast cells and hematopoietic stem and progenitor cells.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody designed to block c-Kit activity.